{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:49:46Z","timestamp":1762642186269,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Exp Pathol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Programmed cell death ligand 1 (PD-L1) is a predictive biomarker of the response of immunotherapy in some types of cancer. In the last years it was described its expression in breast cancer, namely in triple-negative breast cancer (TNBC) cases. In order to better understand the prognostic value of PD-L1 in breast cancer, this study analysed its expression in a series of primary tumours and respective nodal metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PD-L1 expression was evaluated by immunohistochemistry in a series of 52 breast cancer cases and paired lymph node metastasis and correlate with the clinicopathological features of the primary tumour. The TNBC cases were re-classified using morphological and immunohistochemistry surrogate markers and the expression of PD-L1 was correlate with the different subtypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>It was observed that the majority of the cases with PDL-1 positive in the nodal metastasis did not express PD-L1 in the primary tumour (90.0%, 10 out of 11 cases). In addition, from the cases with a negative PD-L1 expression in the primary tumour, 23.8% expressed PD-L1 in the metastasis (10 out of 42 cases).No relationship was found between the PD-L1 expression in nodal metastasis and the clinicopathological features of the primary tumour. Finally, basal-like immunosuppressed (BLIS) TN tumours seem to be less prone to express PD-L1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although without statistical significance, there is a gain in terms of the PD-L1 expression in the nodal metastasis when compared to the primary tumour. This may have therapeutic implications on immunotherapy that blocks the PD-1\/PD-L1 pathway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42047-019-0033-z","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T01:07:56Z","timestamp":1551402476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Expression of PD-L1 in primary breast carcinoma and lymph node metastases"],"prefix":"10.1186","volume":"2","author":[{"given":"Alice M.","family":"Alves","sequence":"first","affiliation":[]},{"given":"Joana","family":"Paredes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-8681","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"33_CR1","doi-asserted-by":"publisher","unstructured":"Botti G, Collina F, Scognamiglio G, Rao F, Peluso V, De Cecio R et al (2017) Programmed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients. Int J Mol Sci 18:459. https:\/\/doi.org\/10.3390\/ijms18020459.","DOI":"10.3390\/ijms18020459"},{"key":"33_CR2","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA et al (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688\u20131698.","journal-title":"Clin Cancer Res"},{"key":"33_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/PAS.0000000000000780","volume":"41","author":"EA Dill","year":"2017","unstructured":"Dill EA, Gru AA, Atkins KA, Friedman LA, Moore ME, Bullock TN et al (2017) PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol 41:334\u2013342.","journal-title":"Am J Surg Pathol"},{"key":"33_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800.","journal-title":"Nat Med"},{"key":"33_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1593\/neo.05733","volume":"8","author":"H Ghebeh","year":"2006","unstructured":"Ghebeh H, Mohammed S, Al-Omair A et al (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190\u2013198.","journal-title":"Neoplasia"},{"key":"33_CR6","volume-title":"Breast Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012","author":"Globocan","year":"2012","unstructured":"Globocan. Breast Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2012 Available from: http:\/\/globocan.iarc.fr\/old\/FactSheets\/cancers\/breast-new.asp. Accessed 12 June 2018."},{"key":"33_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000453569","volume":"11","author":"AD Hartkopf","year":"2016","unstructured":"Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Kramer B, Grischke EM et al (2016) PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care (Basel) 11:385\u2013390.","journal-title":"Breast Care (Basel)"},{"key":"33_CR8","doi-asserted-by":"publisher","unstructured":"Iwai Y, Hamanishi J, Chamoto K, Honjo T (2017) Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci: 24(1)24\u201326. https:\/\/doi.org\/10.1186\/s12929-017-0329-9.","DOI":"10.1186\/s12929-017-0329-9"},{"key":"33_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/imt-2017-0066","volume":"9","author":"A Javed","year":"2017","unstructured":"Javed A, Arguello D, Johnston C, Gatalica Z, Terai M et al (2017) PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 9:1323\u20131330.","journal-title":"Immunotherapy"},{"key":"33_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10549-014-2984-9","volume":"145","author":"P Karasar","year":"2014","unstructured":"Karasar P, Esendagli G (2014) T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat 145:605\u2013614.","journal-title":"Breast Cancer Res Treat"},{"key":"33_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2017.01.004","volume":"75","author":"S Kim","year":"2017","unstructured":"Kim S, Koh J, Kwon D, Keam B, Go H et al (2017) Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. Eur J Cancer 75:141\u2013149.","journal-title":"Eur J Cancer"},{"key":"33_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12885-017-3916-y","volume":"18","author":"M Li","year":"2018","unstructured":"Li M, Li A, Zhou S, Xu Y, Xiao Y et al (2018) Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer 18:4. https:\/\/doi.org\/10.1186\/s12885-017-3916-y.","journal-title":"BMC Cancer"},{"key":"33_CR13","doi-asserted-by":"publisher","unstructured":"Liu D, Wang S, Bindeman W (2017) Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol: 10\u201311. https:\/\/doi.org\/10.1186\/s13045-017-0479-y","DOI":"10.1186\/s13045-017-0479-y"},{"key":"33_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","volume":"132","author":"SM Mahmoud","year":"2012","unstructured":"Mahmoud SM, Lee AH, Paish EC et al (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132:545\u2013553.","journal-title":"Breast Cancer Res Treat"},{"key":"33_CR15","doi-asserted-by":"publisher","unstructured":"Martins D, Schmitt F (2018) Microenvironment in breast tumorigenesis: friend or foe? Histol Histopathol:18021. https:\/\/doi.org\/10.14670\/HH-18-021..","DOI":"10.14670\/HH-18-021."},{"key":"33_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s00428-005-0010-7","volume":"447","author":"I Matos","year":"2005","unstructured":"Matos I, Dufloth R, Alvarenga M et al (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447:688\u2013694.","journal-title":"Virchows Arch"},{"key":"33_CR17","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1200\/JCO.2008.17.9036","volume":"27","author":"A Merlo","year":"2009","unstructured":"Merlo A, Casalini P, Carcangiu ML et al (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746\u20131752.","journal-title":"J Clin Oncol"},{"key":"33_CR18","doi-asserted-by":"publisher","unstructured":"Nanda R, Saha P (2016) Immune checkpoint inhibition for triple-negative breast cancer. Oncol Hematol Rev (US) 12. https:\/\/doi.org\/10.17925\/OHR.2016.12.01.31","DOI":"10.17925\/OHR.2016.12.01.31"},{"key":"33_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jclinpath-2016-203990","volume":"70","author":"A Pol\u00f3nia","year":"2017","unstructured":"Pol\u00f3nia A, Pinto R, Cameselle -Teijeiro J, Schmitt F, Paredes J (2017) Prognostic value of stromal tumor infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. J Clin Pathol 70:860\u2013867.","journal-title":"J Clin Pathol"},{"key":"33_CR20","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.18632\/oncotarget.3216","volume":"6","author":"R Sabatier","year":"2015","unstructured":"Sabatier R, Finetti P, Mamessier E et al (2015) Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 6:5449\u20135464.","journal-title":"Oncotarget"},{"key":"33_CR21","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"AN Seo","year":"2013","unstructured":"Seo AN, Lee HJ, Kim EJ et al (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705\u20132713.","journal-title":"Br J Cancer"},{"key":"33_CR22","first-page":"130","volume":"32","author":"B Sz\u00e9kely","year":"2017","unstructured":"Sz\u00e9kely B, Silber ALL, Pusztai L (2017) New therapeutic strategies for triple -negative breast cancer. J Oncol 32:130\u2013137.","journal-title":"J Oncol"},{"key":"33_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287.","journal-title":"Nat Rev Cancer"},{"key":"33_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/1751-2980.12538","volume":"18","author":"HB Wang","year":"2017","unstructured":"Wang HB, Yao H, Li CS, Liang LX, Zhang Y et al (2017) Rise of PD-L1 expression during metastasis of colorectal cancer: implications for immunotherapy. J Dig Dis 18:574\u2013581.","journal-title":"J Dig Dis"},{"key":"33_CR25","doi-asserted-by":"publisher","unstructured":"Yu LY, Tang J, Zhang CM, Zeng WJ, Yan H, Li MP et al (2017) New immunotherapy strategies in breast cancer. Int J Environ Res Public Health 14(1), 68. https:\/\/doi.org\/10.3390\/ijerph14010068.","DOI":"10.3390\/ijerph14010068"},{"key":"33_CR26","doi-asserted-by":"crossref","first-page":"31347","DOI":"10.18632\/oncotarget.15532","volume":"8","author":"M Zhang","year":"2017","unstructured":"Zhang M, Sun H, Zhao S, Wang Y, Pug H, Wang Y et al (2017) Expression of PD-L1 and prognosis in breast cancer: a metaanalysis. Oncotarget 8:31347\u201331354.","journal-title":"Oncotarget"}],"container-title":["Surgical and Experimental Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42047-019-0033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42047-019-0033-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42047-019-0033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T14:09:08Z","timestamp":1638367748000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgexppathol.biomedcentral.com\/articles\/10.1186\/s42047-019-0033-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1186\/s42047-019-0033-z","relation":{},"ISSN":["2520-8454"],"issn-type":[{"type":"electronic","value":"2520-8454"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"1 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with national regulative law for the handling of biological specimens from tumour banks, the samples being exclusively available for the research purposes in retrospective studies as well as under the international Helsinki declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"7"}}